A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-2
- Sponsors Janssen Research & Development
- 21 Apr 2017 Planned primary completion date changed from 24 Mar 2017 to 6 Jun 2017.
- 29 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 18 Jul 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2017.